Fernand Labrie
Publications
Page 4 of 8, showing 50 records out of 361 total, starting on record 151, ending on 200
| Publication | Category | Year |
|---|---|---|
| 211. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Diamond, P., Koutsilieris, M., Suburu, R., Fradet, Y., Lemay, M., Tetu, B., Emond, J., Candas, B. (1993) Downstaging of localized prostate cancer by neoadjuvant therapy with Flutamide and Lupron. Clin. Invest. Med., 16: 499-509. | Prostate Cancer | 1993 |
| 210. Labrie, F., Dupont, A., Simard, J., Luu-The, V., Bélanger, A. (1993) Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur. Urol., 24 Suppl. 2: 94-105. | Prostate Cancer | 1993 |
| 209. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Gomez, J.L., Koutsilieris, M., Diamond, P., Emond, J., Lemay, M., Candas, B. (1993) Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin. Invest. Med., 16: 425-439. | Prostate Cancer | 1993 |
| 208. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1993) Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA. Mol. Cell. Endocrinol., 91: 43-49. | Prostate Cancer | 1993 |
| 207. Normand, T., Narod, S., Labrie, F., Simard, J. (1993) Detection of polymorphisms in the estradiol 17?-hydroxysteroid dehydrogenase II gene at the human EDH17B2 locus on 17q11-q21. Hum. Mol. Genet., 2: 479-483. | Prostate Cancer | 1993 |
| 206. Gomez, J.L., Dupont, A., Cusan, L., Tremblay, M., Suburu, E.R., Lemay, M., Labrie, F. (1992) Incidence of liver toxicity associated with the use of Flutamide in prostate cancer patients. Am. J. Med., 92: 465-470. | Prostate Cancer | 1992 |
| 205. Gomez, J.L., Dupont, A., Cusan, L., Tremblay, M., Tremblay, M., Labrie, F. (1992) Simultaneous liver and lung toxicity related to the non-steroidal antiandrogen Nilutamide (Anandron): a case report. Am. J. Med., 92: 563-566. | Prostate Cancer | 1992 |
| 204. Labrie, F. (1992) Stratégie efficace et peu coûteuse pour la détection du cancer de la prostate à un stade précoce alors que la guérison est possible. Médecine/Sciences, 8: 703-706. | Prostate Cancer | 1992 |
| 203. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Emond, J., Monfette, G. (1992) Combination therapy with Flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer (8-year clinical experience) and extension to early stages of the diseases, in: Carpi, A., Sagripanti, A. et Mittermayer, eds: Progress in Clinical Oncology, Italy, Sympomed Verlag, pp 278-293. | Prostate Cancer | 1992 |
| 202. Labrie, F., Dupont, A., Cusan, L., Suburu, E.R., Gomez, J.L., Thibault, M.M., Tremblay, M. (1992) Perspectives dans le diagnostic et le traitement du cancer de la prostate au stade précoce, in: Bonjour, J.P., Gayraud, M.,Guillevin, L. et Rizzoli, R., eds: Nouvelles statégies thérapeutiques en cancérologie, rapports présentés au XLVIIIe Congrès Français de Médecine, Montréal 1991, Alertes carcinologiques, pp 25-44. | Prostate Cancer | 1992 |
| 201. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.L., Emond, J. (1992) Serum prostate specific antigen (PSA) as prescreening test for prostate cancer. J. Urol., 147: 846-851. | Prostate Cancer | 1992 |
| 200. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1992) Blockade of androgen action by combined treatment with a pure antiandrogen (Flutamide) and a 5?-reductase inhibitor (4-MA), in: Giuliani, L. et Puppo, P., eds: Urology, Bologna, Monduzzi Editore, pp 605-610. | Prostate Cancer | 1992 |
| 199. Pinault, S., Têtu, B., Gagnon, J., Monfette, G., Dupont, A., Labrie, F. (1992) Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination therapy with flutamide. Urology, 39: 254-261. | Prostate Cancer | 1992 |
| 198. Bélanger, A., Brochu, M., Lacoste, D., Noel, C., Labrie, F., Dupont, A., Cusan, L., Caron, S., Couture, J. (1991) Steroid glucuronides: human circulatory levels and formation by LNCaP cells. J. Steroid Biochem. Mol. Biol., 40: 593-598. | Prostate Cancer | 1991 |
| 197. de Launoit, Y., Veilleux, R., Dufour, M., Simard, J., Labrie, F. (1991) Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res., 51: 5165-5170. | Prostate Cancer | 1991 |
| 196. Dupont, A., Cusan, L., Gomez, J.-L., Thibeault, M.M., Tremblay, M., Labrie, F. (1991) Prostatic specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J. Urol., 146: 1064-1068. | Prostate Cancer | 1991 |
| 195. Labrie, C., Trudel, C., Li, S., Martel, C., Couet, J., Labrie, F. (1991) Combination of an antiandrogen and a 5?-reductase inhibitor: a further step towards total androgen blockade? Endocrinology, 129: 566-568. | Prostate Cancer | 1991 |
| 194. Labrie, F. (1991) Endocrine therapy for prostate cancer, in: Strauss, J.F., ed. Endocrinology and Metabolism Clinics of North America, Philadelphia, W.B. Saunders, pp 845-872. | Prostate Cancer | 1991 |
| 193. Labrie, F. (1991) Intracrinology. Mol. Cell. Endocrinol., 78: C113-C118. | Prostate Cancer | 1991 |
| 192. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Lacourcière, Y., Monfette, G., Emond, J. (1991) Maximal androgen blockade in prostate cancer: To-Day's Therapy of choice and 5-year clinical experience, in: Vickery, B.H. et Lunenfeld, B., eds: International Symposium on GnRH analogues in Cancer and Human Reproduction, The Netherlands, Kluwer Academic Publishers, pp 79-102. | Prostate Cancer | 1991 |
| 191. Simard, J., Veilleux, R., de Launoit, Y., Haagensen, D.E., Labrie, F. (1991) Stimulation of apoliprotein D secretion by steroids coincide with inhibition of cell proliferation in LNCaP prostate cancer cells. Cancer Res., 51: 4336-4341. | Prostate Cancer | 1991 |
| 190. Têtu, B., Srigley, J.R., Boivin, J.C., Dupont, A., Monfette, G., Pinault, S., Labrie, F. (1991) Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: a histopathologic and immunohistochemical study. Am. J. Surg. Pathol., 15: 111-120. | Prostate Cancer | 1991 |
| 189. Bélanger, C., Veilleux, R., Labrie, F. (1990) Stimulatory effects of androgens, estrogens, progestins dexamethasone on the growth of the LNCaP human prostate cancer cells, in: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds: Steroid Formation, Degradation and Action in Peripheral, Normal and Neoplastic Tissues, Ann. New York Acad. Sci., pp 399-402. | Prostate Cancer | 1990 |
| 188. Candas, B., Lacoste, D., Normand, M., Labrie, F. (1990) Model of the distribution and metabolism of the gonadotropin-releasing hormone (GnRH) agonist [D-Trp6,Des-Gly-NH2(10)]GnRH ethylamide in man. J. Clin. Endocrinol. Metab., 70: 1046-1054. | Prostate Cancer | 1990 |
| 187. Dupont, A., Boucher, H., Cusan, L., Lacourcière, Y., Emond, J., Labrie, F. (1990) Octreotide and bromocriptine in patients with stage D2 prostate cancer who relapsed during treatment with Flutamide and castration. Eur. J. Cancer, 26: 770-771. | Prostate Cancer | 1990 |
| 186. Labrie, C., Simard, J., Poulin, M., Bélanger, A., Pelletier, G., Labrie, F. (1990) Influence of the duration of androgen deprivation on the sensitivity of the rat ventral prostate to dehydroepiandrosterone and androstenedione, in: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds: Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues, Ann. New York Acad. Sci., pp 392-394. | Prostate Cancer | 1990 |
| 185. Labrie, C., Simard, J., Zhao, H.F., Bélanger, A., Pelletier, G., Labrie, F. (1990) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate, in: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds: Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues, Ann. New York Acad. Sci., pp 395-398. | Prostate Cancer | 1990 |
| 184. Labrie, C., Simard, J., Zhao, H.F., Pelletier, G., Labrie, F. (1990) Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Mol. Cell. Endocrinol., 68: 169-179. | Prostate Cancer | 1990 |
| 183. Labrie, F. (1990) Goserelin study criticized. Oncology Times, 10: 18-19. | Prostate Cancer | 1990 |
| 182. Labrie, F. (1990) Peripheral tissues are important sites of sex steroid formation in the human: a new area of endocrinology which extends from gene structure to the first therapy that prolongs life in prostate cancer. Physiol, 21: 66-69. | Prostate Cancer | 1990 |
| 181. Labrie, F., Bélanger, A., Dupont, A., Pelletier, G., Luu-The, V., Simard, J., Cusan, L., Labrie, C., Lachance, Y., Poulin, R., Dupont, E., Zhao, H.F., Martel, C. (1990) Synthèse périphérique des androgènes chez l'homme. Génétique moléculaire du système et sa prise en compte dans le traitement du cancer de la prostate. Médecine/Sciences, 6: 261-267. | Prostate Cancer | 1990 |
| 180. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Emond, J., Monfette, G. (1990) Combination therapy with Flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience. J. Steroid Biochem. Mol. Biol., 37: 943-950. | Prostate Cancer | 1990 |
| 179. Lacoste, D., Bélanger, A., Labrie, F. (1990) Biosynthesis and degradation of androgens in human prostatic cancer cell lines, in: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds: Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues, Ann. New York Acad. Sci., pp 389-391. | Prostate Cancer | 1990 |
| 178. Lacoste, D., Candas, B., Normand, M., Labrie, F. (1990) Model of the distribution and metabolism of a GnRH superagonist in dogs. Am. J. Physiol., 258: E468-E475. | Prostate Cancer | 1990 |
| 177. Pinault, S., Fortin, D., Gagnon, J., Têtu, B., Dupont, A., Labrie, F. (1990) La biopsie prostatique transrectale sous guide ultrasonore. Radiologie, 10: 313-317. | Prostate Cancer | 1990 |
| 176. Rousseau, L., Couture, M., Dupont, A., Labrie, F., Couture, N. (1990) Effect of combined androgen blockade with an LHRH agonist and Flutamide in one severe case of male exhibitionism. Can. J. Psychiatry, 35: 338-341. | Prostate Cancer | 1990 |
| 175. Bélanger, B., Bélanger, A., Labrie, F., Dupont, A., Cusan, L., Monfette, G. (1989) Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J. Steroid Biochem., 32: 695-698. | Prostate Cancer | 1989 |
| 174. Dupont, A., Labrie, F., Manhès, G., Bergeron, N., Cusan, L., Pinault, S., Bélanger, A., Boucher, M., Lacourcière, Y., Emond, J. (1989) Combination therapy with Flutamide and the LHRH agonist [D-Trp6, des-Gly-NH210]LHRH ethylamide in stage C prostatic carcinoma, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 89-102. | Prostate Cancer | 1989 |
| 173. Emond, J., Dupont, A., Cusan, L., Bergeron, N., Manhès, G., Labrie, F. (1989) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) as an alternative to transurethral resection of the prostate for urinary retention in prostate cancer, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, pp 103-108. | Prostate Cancer | 1989 |
| 172. Labrie, C., Simard, J., Marchetti, B., Pelletier, G., Zhao, H.F., Bélanger, A., Labrie, F. (1989) Conversion of precursor adrenal steroids into potent androgens in peripheral tissue, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 1-22. | Prostate Cancer | 1989 |
| 171. Labrie, C., Simard, J., Zhao, H., Bélanger, A., Pelletier, G., Labrie, F. (1989) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 124: 2745-2754. | Prostate Cancer | 1989 |
| 170. Labrie, F. (1989) Criteria of response of stage D2 prostate cancer [Letter to the Editor: Reply to Newling et al. re 24: 1869-78, 1988]. Eur. J. Cancer Clin. Oncol., 25: 1259-1260. | Prostate Cancer | 1989 |
| 169. Labrie, F. (1989) Medical treatment of prostate cancer. Drug Therapy, 19: 22-37. | Prostate Cancer | 1989 |
| 168. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Brochu, M., Turina, E., Pinault, S., Lacourcière, Y., Emond, J. (1989) Anti-hormone treatment in stage D2 prostate cancer patients relapsing under treatment with Flutamide and castration: addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br. J. Urol., 63: 634-638. | Prostate Cancer | 1989 |
| 167. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Lacourcière, Y., Bélanger, A., Monfette, G., Emond, J. (1989) Terapia combinada con flutamida y (D-TRP6)LH-RH etilamida en el cancer de prostata en estadio D2 sin tratamiento previo, in: Pontes, J.E., Mallo, N. et Zungri, E., eds: Cancer de Prostata, ulso Ediciones, Barcelona, Actualizaciones Urologicas, pp 73-86. | Prostate Cancer | 1989 |
| 166. Labrie, F., Dupont, A., Cusan, L., Labrie, C., Lacoste, D., Luu-The, V., Manhès, G., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Today's endocrine therapy of prostate cancer, in Fourth International Symposium on Transrectal Ultrasound in the Diagnosis and Management of Prostate Cancer, New York, Alan R. Liss Inc., pp 223-235. | Prostate Cancer | 1989 |
| 165. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Combination therapy with castration and flutamide: to-day's treatment of choice for prostate cancer. J. Steroid Biochem., 33: 817-821. | Prostate Cancer | 1989 |
| 164. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Combination therapy with Flutamide and castration: its benefits at various stages of prostate cancer, in: Murphy, G.P. et Khoury, S., eds: Progress in Clinical and Biological Research, New York, Alan R. Liss Inc., pp 161-167. | Prostate Cancer | 1989 |
| 163. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) LHRH agonists and prostate cancer: an example of rapid development of a new class of drugs, in: Chiou, S.H., Wang, K.T. et Wu, S.H., eds: International Symposium on Biologically Active Proteins and Peptides, July 13-15, 1988, Taipei, Taiwan, pp 129-136. | Prostate Cancer | 1989 |
| 162. Lacoste, D., Caron, S., Bélanger, A., Labrie, F. (1989) Effect of 3-week treatment with [D-Trp6, des-Gly-NH210]LHRH ethylamide, aminoglutethimide, ketoconazole or Flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog. J. Steroid Biochem., 33: 233-242. | Prostate Cancer | 1989 |